Citizens Financial Group Inc. RI Boosts Stock Position in Bristol Myers Squibb Company $BMY

Citizens Financial Group Inc. RI grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 53.6% during the first quarter, Holdings Channel reports. The firm owned 80,552 shares of the biopharmaceutical company’s stock after acquiring an additional 28,098 shares during the period. Citizens Financial Group Inc. RI’s holdings in Bristol Myers Squibb were worth $4,885,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Sovran Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 53.7% in the 1st quarter. Sovran Advisors LLC now owns 8,724 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 3,047 shares during the last quarter. American Trust acquired a new stake in shares of Bristol Myers Squibb in the first quarter worth $346,000. WealthShield Partners LLC raised its holdings in shares of Bristol Myers Squibb by 6.0% during the first quarter. WealthShield Partners LLC now owns 11,565 shares of the biopharmaceutical company’s stock worth $701,000 after purchasing an additional 658 shares during the last quarter. Simplicity Wealth LLC lifted its position in Bristol Myers Squibb by 25.5% during the first quarter. Simplicity Wealth LLC now owns 11,504 shares of the biopharmaceutical company’s stock valued at $698,000 after purchasing an additional 2,340 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in Bristol Myers Squibb by 9.9% during the first quarter. Sequoia Financial Advisors LLC now owns 168,316 shares of the biopharmaceutical company’s stock valued at $10,208,000 after purchasing an additional 15,178 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 0.1%

Shares of NYSE:BMY opened at $57.53 on Monday. The business’s 50 day moving average price is $56.83 and its 200-day moving average price is $57.64. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The firm has a market capitalization of $117.49 billion, a price-to-earnings ratio of 16.16, a price-to-earnings-growth ratio of 0.16 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BMY shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Bank of America lowered their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a report on Thursday, July 2nd. Finally, HSBC lifted their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $61.25.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bank of America lowered its price target slightly to $66 from $67 but kept a Buy rating, signaling continued upside potential for Bristol Myers Squibb. Benzinga
• Positive Sentiment: Bristol Myers Squibb’s addition to defensive and value-defensive Russell indices could broaden demand from index-tracking and conservative institutional investors. Yahoo Finance
• Positive Sentiment: The company’s QUILS lung cancer detection program is expanding into new states, reinforcing its reputation in oncology and public-health initiatives. Yahoo Finance

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.